Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

by Jabbour, E., Kantarjian, H.M., Saglio, G., Steegmann, J.L., Shah, N.P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., Baccarani, M., Kim, D.-W., Bradley-Garelik, M.B., Mohamed, H., Wildgust, M., Hochhaus, A.
Published 2016